❋

Technical Due Diligence for Multi-Billion Dollar Cell Therapy Platform Investment

About Client

The client is a global pharmaceutical company evaluating a strategic investment in an iPSC-based cell therapy platform with potential downstream value exceeding hundreds of millions. The investment required comprehensive technical assessment to validate platform viability and development risks.

Study: Independent technical due diligence and investment recommendation for transformational cell therapy platform acquisition

Challenge

Support in making a $3B+ investment decision

  • Leadership required a rigorous technical validation to support board-level approval for a cell therapy platform

  • Complex iPSC platform technology involving novel differentiation methodologies and manufacturing processes required deep domain expertise

  • Eight-week timeline to deliver comprehensive assessment of technical risks, competitive positioning, and probability of success

Solution

Conducted a systematic evaluation of the iPSC differentiation platform

  • Assessed process robustness, scalability, IP landscape, and competitive differentiation across multiple therapeutic applications

  • Performed deep technical review of preclinical data packages, gap analysis, and benchmarking against successful cell therapy programs to validate development path

  • Developed risk assessment framework with quantified probability of technical success and a milestone-based investment structure

Results

The engagement enabled confident, data-driven investment decision with measurable risk reduction and strategic clarity

  • Delivered technical recommendation enabling leadership approval of strategic investment within target timeline

  • Technical assessment framework applied to subsequent acquisition evaluations, improving due diligence efficiency and decision quality